Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Predictors of Recurrence, Progression-Free and Overall Survival Following Open Versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Follow-Up. The Journal of urology Venkatramani, V. n., Reis, I. M., Castle, E. P., Gonzalgo, M. L., Woods, M. E., Svatek, R. S., Weizer, A. Z., Konety, B. R., Tollefson, M. n., Krupski, T. L., Smith, N. D., Shabsigh, A. n., Barocas, D. A., Quek, M. L., Dash, A. n., Kibel, A. S., Pruthi, R. S., Montgomery, J. S., Weight, C. J., Sharp, D. S., Chang, S. S., Cookson, M. S., Gupta, G. N., Gorbonos, A. n., Uchio, E. M., Skinner, E. n., Soodana-Prakash, N. n., Becerra, M. F., Swain, S. n., Kendrick, K. n., Smith, J. A., Thompson, I. M., Parekh, D. J. 2019: 101097JU0000000000000565

Abstract

The randomized open versus robotic cystectomy (RAZOR) trial reported non-inferior 2-year progression-free survival (PFS) for robotic radical cystectomy (RARC). This update was performed with extended follow-up for 3 years to demonstrate potential differences between the approaches. We also report 3-year overall survival (OS) and aim to identify factors predicting recurrence, PFS and OS.The per-protocol population of 302 patients from RAZOR study was analyzed. Cumulative recurrences were estimated using non-bladder cancer death as the competing risk event and Gray's test was used to assess significance in differences. PFS and OS were estimated by Kaplan-Meier method and compared using the log rank test. Predictors of outcomes were determined by Cox proportional hazard analysis.Estimated PFS at 36 months was 68.4% (95% CI 60.1-75.3%) and 65.4% (95% CI 56.8-72.7%) in the robotic and open groups respectively (p=0.600). OS at 36 months was 73.9% (95% CI 65.5-80.5%) and 68.5% (95% CI 59.8-75.7%) for the robotic and open group respectively (p=0.334). There was no significant difference in the cumulative incidence rates of recurrence (p=0.802). Age >70 years, poor performance status and major complications were significant predictors of PFS and OS. Stage and positive margins were significant predictors of recurrence, PFS and OS. Surgical approach was not a significant predictor of any outcome.This analysis shows no difference in recurrence, 3-year PFS and 3-year OS between RARC and ORC. It provides important prospective data on the oncologic efficacy of RARC and high-level data for patient counseling.

View details for DOI 10.1097/JU.0000000000000565

View details for PubMedID 31549935